A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
Sarah Leary
Research Funding - Amgen
Julie R. Park
No relevant relationships to disclose
Joel M. Reid
No relevant relationships to disclose
Andrew T. Ralya
No relevant relationships to disclose
Sylvain Baruchel
Research Funding - Amgen
Bing Wu
Research Funding - Amgen
Ashish M Ingle
No relevant relationships to disclose
Charlotte H Ahern
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose